While proteinopathies like amyloid-beta and phosphorylated tau are hallmark biomarkers for diagnosing AD, recent literature suggests they do not always effectively predict cognitive decline, especially in cognitively unimpaired people or at the MCI stage (e.g., Dubois et al., 2024).126. The gene discussed is MAPT; the disease is proteostasis deficiencies.